Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies
| Autor: | Dario Kivelevitch, Jason Lichten, April W. Armstrong, Robert S. Rahimi, Emily B. Wong, Reena N. Rupani, Nehal N. Mehta, Alan Menter, Neil J. Korman, Craig A. Elmets, Amy S. Paller, Arun L. Pathy, Craig L. Leonardi, Arthur Kavanaugh, Boni E. Elewski, Matthew Kiselica, Daniel H. Kaplan, Sylvia L. Parra, Michael Siegel, Benjamin K. Stoff, Dawn Marie R. Davis, Mark Lebwohl, Kenneth B. Gordon, Alice B. Gottlieb, Cody Connor, Jashin J. Wu, Bruce Strober, Kelly M. Cordoro, Elizabeth Farley Prater, Elliot B. Tapper, Vidhya Hariharan, Henry W. Lim, Daniela Kroshinsky, Joel M. Gelfand |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Population Dermatology Acitretin 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Piperidines Psoriasis Area and Severity Index Psoriasis medicine Humans education education.field_of_study Tofacitinib business.industry Guideline medicine.disease Tacrolimus Thalidomide Methotrexate Pyrimidines 030220 oncology & carcinogenesis Cyclosporine Apremilast Drug Monitoring business medicine.drug |
| Zdroj: | Journal of the American Academy of Dermatology. 82:1445-1486 |
| ISSN: | 0190-9622 |
| Popis: | Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect